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Abstract
In the case of an influenza pandemic, the current global influenza vaccine production capacity will be unable to meet the
demand for billions of vaccine doses. The ongoing threat of an H5N1 pandemic therefore urges the development of highly
immunogenic, dose-sparing vaccine formulations. In unprimed individuals, inactivated whole virus (WIV) vaccines are more
immunogenic and induce protective antibody responses at a lower antigen dose than other formulations like split virus (SV)
or subunit (SU) vaccines. The reason for this discrepancy in immunogenicity is a long-standing enigma. Here, we show that
stimulation of Toll-like receptors (TLRs) of the innate immune system, in particular stimulation of TLR7, by H5N1 WIV vaccine
is the prime determinant of the greater magnitude and Th1 polarization of the WIV-induced immune response, as compared
to SV- or SU-induced responses. This TLR dependency largely explains the relative loss of immunogenicity in SV and SU
vaccines. The natural pathogen-associated molecular pattern (PAMP) recognized by TLR7 is viral genomic ssRNA. Processing
of whole virus particles into SV or SU vaccines destroys the integrity of the viral particle and leaves the viral RNA prone to
degradation or involves its active removal. Our results show for a classic vaccine that the acquired immune response evoked
by vaccination can be enhanced and steered by the innate immune system, which is triggered by interaction of an intrinsic
vaccine component with a pattern recognition receptor (PRR). The insights presented here may be used to further improve
the immune-stimulatory and dose-sparing properties of classic influenza vaccine formulations such as WIV, and will facilitate
the development of new, even more powerful vaccines to face the next influenza pandemic.
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Introduction
The first cases of human infection with highly pathogenic avian
influenza (HPAI) H5N1 virus occurred in 1997 during an
outbreak in Hong Kong [1]. Since then HPAI H5N1 has spread
across Asia, Europe, Africa and the Pacific, and has caused a
cumulative number of 338 laboratory confirmed human cases of
infection, with a fatality rate of .60% [2]. Although no sustained
human to human transmission has been observed yet, the threat of
an imminent H5N1 pandemic requires maximum preparedness
[3]. Vaccination is considered the cornerstone of protection
against epidemic and pandemic influenza. However, an anticipat-
ed scarcity of the antigenic vaccine components and a narrowed
time window between vaccine production and deployment puts
special constraints on the vaccine formulation to be used in a
pandemic situation [4,5]. Consequently, pandemic vaccine
formulations should ideally be dose sparing and uncomplicated
to produce [6,7].
Whole inactivated virus (WIV) vaccines consisting of formalin-
inactivated whole virus particles were the first registered influenza
vaccines licensed in 1945 in the United States [8]. However, the
use of this vaccine formulation caused a relatively high incidence
of adverse events, including local reactions at the site of injection
and febrile illness, particularly among children [9,10]. In the 1960
and 1970s, WIV vaccines were therefore largely replaced by less
reactogenic split virus (SV) and subunit (SU) formulations [8]. SV
and SU vaccines contain detergent- and/or ether-disrupted (split)
virus particles or purified viral haemagglutinin (HA) and
neuraminidase (NA) proteins, respectively. Apparently, disruption
of whole inactivated influenza virus particles diminishes the
reactogenicity of the vaccines.
In primed individuals, unadjuvanted WIV, SV, and SU
vaccines in general induce similar immune responses in terms of
haemagglutination inhibition (HI) titres (for a meta-analysis over
24 studies see [11]). However, in individuals that have not been
exposed to the vaccine antigens before, WIV vaccines are more
immunogenic than SV and SU vaccines [9,11,12]. Similarly, in
naı ¨ve animals immunization with WIV raises stronger immune
responses than immunization with SV or SU [13–15], especially
after a single administration. In the case of an H5N1 pandemic,
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naı ¨ve to the H5N1 subtype. In this scenario, use of WIV as basis
for an optimized vaccine may be of advantage, for its
immunogenic superiority seems to rely on the ability to activate
unique mechanisms in the priming event of the immune response.
Thus, WIV seems to harbour an intrinsic immune-potentiating
component that is lost during processing of inactivated virus
particles to SV and SU vaccine formulations. In earlier
experiments, we and others observed that immunization of mice
with WIV vaccine results in a Th1-skewed immune response and
strong antibody induction with high levels of IgG2a antibodies
[14–16]. This response type was found irrespective of the murine
genetic background or subtype of virus (either H1N1 or H3N2)
and conferred protective immunity against challenge with
homologous virus [15,16]. By contrast, immunization with SU
vaccine yielded responses of a Th2 phenotype with lower antibody
levels mainly consisting of the IgG1 subtype, which did not lead to
protection. ‘‘Empty’’ reconstituted viral envelopes (virosomes)
resembling intact virus particles but devoid of the viral
nucleocapsid elicited responses similar to those after vaccination
with SU formulations [15]. This identifies the viral nucleocapsid
which contains the viral genomic ssRNA as the immune-
potentiating component of WIV.
In the past decade, it has become increasingly clear that the
acquired immune response to microbial infection is regulated
through recognition of pathogen-associated molecular patterns
(PAMPs) by Toll-like receptors (TLRs) and other pattern
recognition receptors of the innate immune system [17–20].
However, the importance of TLR signalling in immune responses
to vaccines remains largely unclear. A recent study showed that
TLR signalling is not important for the antibody-enhancing effect
of classical vaccine adjuvants such as Complete Freund’s adjuvant
(CFA) [21]. Since CFA contains dried mycobacteria, and therefore
mycobacterial PAMPs [17], this observation casts doubt on the
importance of PAMPs and TLRs in augmenting immune
responses to vaccination. Influenza viral genomic ssRNA is a
natural PAMP recognized by TLR7 [22]. Here, we investigate
whether PAMP recognition by TLRs, in particular recognition of
viral ssRNA by TLR7, is responsible for the superior response to
WIV vaccines compared to SV and SU influenza vaccine
formulations.
Results/Discussion
To analyze the role of ssRNA and other PAMPs in the response
to influenza vaccines in detail, we immunized wild-type C57BL/6
mice, TLR7 knock-out mice, and MyD88/TRIF double knock-
out mice with different vaccine formulations. MyD88 (myeloid
differentiation factor 88) is an adaptor molecule which functions
downstream of all known TLRs and IL1R family members with
the exception of TLR3, which instead recruits a MyD88-related
adapter molecule, TRIF (TIR domain-containing adaptor protein
inducing interferon b) [17]. Consequently, a deficiency of both
MyD88 and TRIF excludes signalling by all TLRs. Mice were
immunized intramuscularly with b-propiolactone-inactivated
H5N1 (NIBRG-14) WIV, SV, or SU vaccine. Quantitative PCR
using primers specific for segment 7 of the viral genome revealed
that WIV contained per vaccine dose at least 5610
8 copies of viral
RNA, the natural ligand of TLR7. In SU or SV vaccine the
amount of RNA was 500 and 5,000 times lower than in WIV,
respectively. Four weeks after immunization, serum and spleen
cells were collected for evaluation of humoral and cellular immune
responses.
Serum HI titres in WIV-immunized TLR7
2/2 mice and
MyD88
2/2/TRIF
2/2 mice were found to be significantly lower
than in WIV-immunized wild-type mice (Figure 1A; p=0.021 and
p=0.001, respectively). Although sera from TLR7
2/2 mice
immunized with WIV showed a higher geometric mean titre
(GMT) than sera from WIV-immunized MyD88
2/2/TRIF
2/2
mice, this difference was not significant (p=0.053). Most of the HI
titres of SV- and SU-immunized wild-type mice were below
detection level, precluding evaluation of the effect of the knock-out
mutations on the HI responses to these vaccines.
Similar to the HI titres, virus neutralization (VN) titres of pooled
serum samples from mice immunized with WIV were lower in the
knock-out groups than in the wild-type group (Table 1). These
results clearly show that TLR signalling is critically involved in the
response to WIV immunization. Yet, in the knock-out groups, VN
titres obtained after immunization with WIV were still modestly
higher than those obtained after vaccination of wild-type mice
with the other vaccines. This points to TLR-independent
pathways contributing to the superior antibody response to WIV
vaccine.
Serum titres of H5N1-specific IgG were determined by ELISA.
In accordance with the HI and VN results, IgG titres were
significantly decreased in WIV-immunized TLR7
2/2 and
MyD88
2/2/TRIF
2/2 mice compared to wild-type mice
(Figure 1B; p=0.010 and p=0.001, respectively). However, like
the VN titres, the IgG titres in the WIV-immunized mutant mice
were still significantly higher than those induced by SV (TLR7
2/2:
p=0.001; MyD88
2/2/TRIF
2/2: p=0.005) or SU (TLR7
2/2:
p=0.005; MyD88
2/2/TRIF
2/2: p=0.021) immunization again
indicating involvement of TLR-independent pathways. The relative
contributions of TLR-dependent and -independent mechanisms to
the superior IgG response to WIV can be estimated by comparing
the difference in geometric mean titre (GMT) between WIV-
immunized wild-type and MyD88/TRIF-deficient mice with the
difference between WIV-immunized wild-type mice and SV- or
SU-immunized wild-type mice. Using this procedure the TLR-
Author Summary
The rise and spread of the highly pathogenic avian H5N1
influenza virus has seriously increased the risk of a new
influenza pandemic. However, the number of vaccine
doses that can be produced with today’s production
capacity will fall short of the demand in times of a
pandemic. Use of inactivated whole virus (WIV) vaccines,
which are more immunogenic than split virus or subunit
vaccines in an unprimed population, could contribute to a
dose-sparing strategy. Yet, the mechanisms underlying the
superior immunogenicity of WIV vaccine formulations are
unknown. Here, we demonstrate that the viral RNA present
in inactivated virus particles is crucial for the improved
immunogenic properties of WIV in mice. By triggering Toll-
like receptor 7 (TLR7), the viral RNA activates innate
immune mechanisms that augment and determine sub-
sequent adaptive responses. Efficient TLR7 signalling is lost
in split virus and subunit vaccines with the processing
steps that lead to disruption of the integrity of the virus
particle and exclusion of the RNA. Our results prove for the
first time to our knowledge that the immune-potentiating
mechanism of a classic vaccine is based on activation of
the innate immune system by one of its structural
components. These findings may reflect a general principle
for viral vaccines and provide a rational basis for further
improvement of influenza vaccines, which are urgently
needed in the face of the current H5N1 pandemic threat.
TLRs Determine Influenza Vaccine Immunogenicity
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versus SV and WIV vs SU, respectively (for calculation, see Text
S1). The IgG responses to SV and SU vaccine in both TLR7
2/2 or
MyD88
2/2/TRIF
2/2 mice did not differ from those in wild-type
mice, except for the IgG response to SU in TLR7
2/2 mice, which
was slightly but significantly decreased (p=0.038; Figure 1B).
Together with the HI and VN results, these findings demonstrate
that the superior antibody response to WIV is predominantly
regulated by TLRs, TLR7 in particular, while TLRs do not seem to
play a prominent role in SV and SU antibody responses.
We next investigated the role of TLRs in the Th1 polarization
of the response characteristically found after WIV vaccination. We
first assessed numbers of IFNc- and IL4- producing T cells (Th1
and Th2 cells, respectively) in a cytokine-specific Elispot assay,
after re-stimulation of spleen cells from immunized mice with
H5N1 SU vaccine. Numbers of Th1 cells were significantly
decreased in WIV-immunized knock-out mice compared to wild-
type mice (p=0.003 and p=0.010 for TLR7
2/2 and MyD88
2/2/
TRIF
2/2 mice, respectively), and matched those found in SV- and
SU-immunized wild-type mice (Figure 2). No difference was found
between TLR7
2/2 and MyD88
2/2/TRIF
2/2 mice. Numbers of
influenza-specific IL4-producing cells were extremely low in all
animals for all vaccine formulations without significant differences
between knock-out and wild-type mice (not shown). These data
indicate that stimulation of TLR7 by ssRNA is the predominant
determinant of the strong Th1-type cellular response induced by
WIV.
We further determined the subtype profiles of H5N1-specific
serum IgG by ELISA (Figure 3). IFNc is known to stimulate
production of IgG2a subtype antibodies by activated B cells, while
IL4 stimulates IgG1 secretion [23]. In C57BL/6 mice, however,
the IgG2c subtype is produced instead of IgG2a [24,25]. Hence, a
predominance of IgG2c or IgG1 is indicative of a Th1- or Th2-
type response, respectively. WIV immunization of TLR7
2/2 mice
as well as MyD88
2/2/TRIF
2/2 mice resulted in significantly
reduced IgG2c levels as compared to wild-type mice (Figure 3;
p=0.001 for both types of knock-out mice), supporting a role for
TLR7 in Th1 polarization. IgG1 was increased in WIV-
immunized TLR7
2/2 mice (P=0.050), adding to the preponder-
Figure 1. TLRs contribute to the efficacy of H5N1 WIV vaccine. Four weeks after immunization of wild-type, TLR7
2/2, and MyD88
2/2/TRIF
2/2
mice with WIV, SV, or SU vaccine (5 mg HA), serum HI titres (A) and H5N1-specific IgG titres (B) were determined for the individual mice. Titres below
the detection limit were assigned with half the value of the lowest detectable serum dilution, which was 8 in the HI assay and 100 in the IgG ELISA.
Significant (p,0.05) and highly significant (p,0.01) differences between wild-type mice and mutant mice receiving the same vaccine are indicated by
* and **, respectively. GMT indicates geometric mean titter.
doi:10.1371/journal.ppat.1000138.g001
Table 1. TLR-dependent and -independent mechanisms
contribute to virus neutralization titres induced by WIV.
Vaccine Mouse Strain VN Titre
wt 640
WIV TLR7
2/2 80
MyD88
2/2/TRIF
2/2 80
wt 20
SV TLR7
2/2 20
MyD88
2/2/TRIF
2/2 40
wt 40
SU TLR7
2/2 20
MyD88
2/2/TRIF
2/2 20
Mouse sera were collected 4 wk after immunization with different vaccine
formulations and pooled per immunization group (n=8 per group, except for
SU immunized MyD88
2/2/TRIF
2/2 mice: n=7) and subsequently submitted to
the VN assay.
doi:10.1371/journal.ppat.1000138.t001
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average of ratios of serum IgG2c and IgG1 concentrations
(determined with appropriate IgG subtype protein standards)
was 17.82 (SD 8.44) for the wild-type mice immunized with WIV,
compared to 0.53 (SD 0.41) for TLR7
2/2 mice immunized with
WIV. SV and SU vaccines induced predominantly IgG1 and low
levels of IgG2c, consistent with a Th2-type response (Figure 3). For
reasons unknown, SU vaccine induced lower IgG1 titres in both
typesofknock-outmicecomparedtothe wild-typemice(TLR7
2/2:
p=0.050;MyD88
2/2/TRIF
2/2:p=0.014).Whetherthepresence
of some residual RNAinSU vaccine might play a role remainsto be
shown.
The response characteristics of the different H5N1 vaccines in
wild-type mice were well in line with those previously found for
other influenza subtypes [15,16]. This consistency is supportive of
a general mechanism underlying the differences in responses to
WIV, SV and SU vaccine, which operates irrespective of the virus
subtype used to vaccinate.
The above results demonstrate that TLR signalling plays an
important role in the magnitude and Th1 skewing of the response
to WIV influenza vaccines. Yet, in TLR-ko mice, WIV remained
more immunogenic than SV and SU vaccines, inducing
significantly higher titres of total IgG (Figure 1B) and Th1-type
antibody subtypes (IgG2b, IgG2c, IgG3; Figure 3; p,0.05 for all
comparisons). Thus, next to TLR-dependent mechanisms, a
(minor) TLR-independent factor seems to contribute to the
superior magnitude and Th1-skewing of the immune response to
WIV. Type I interferons, including IFNa, have been shown to
stimulate antibody responses and isotype switching to IgG2a when
added to influenza subunit vaccine or other protein antigens
Figure 2. Induction of IFNc-producing T cells by H5N1 WIV vaccine depends on TLR7 signalling. Spleen cells of wild-type mice and
mutant mice immunized with WIV, SV, or SU vaccine were re-stimulated in vitro with SU vaccine, and numbers of IFNc-producing cells were
determined by Elispot assay. Bars represent the average values of triplicate determinations per mouse for each mouse type and immunization group
(n=8; MyD88
2/2/TRIF
2/2/SU, n=7), with standard deviation. Significant (p,0.05) and highly significant (p,0.01) differences between wild-type mice
and mutant mice receiving the same vaccine are indicated by * and **, respectively.
doi:10.1371/journal.ppat.1000138.g002
Figure 3. H5N1 WIV vaccine induces Th1-type antibody responses via TLR7 signalling. Serum titres of H5N1-specific IgG1 subtype (Th2-
type antibody), and IgG2c, IgG2b, and IgG3 subtypes (Th1-type antibodies) were determined by ELISA. Geometric mean titres are plotted for each
group of wild-type mice or mutant mice (n=8; MyD88
2/2/TRIF
2/2/SU, n=7) immunized with WIV, SV, or SU vaccine. Significant (p,0.05) and highly
significant (p,0.01) differences between wild-type mice and mutant mice receiving the same vaccine are indicated by * and **, respectively.
doi:10.1371/journal.ppat.1000138.g003
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have previously shown for an H3N2 influenza virus strain that,
unlike SU vaccine, WIV vaccine efficiently induced interferon a
(IFNa) production in plasmacytoid dendritic cells (pDCs) in vitro
[15]. We therefore evaluated the induction of IFNa by the H5N1
influenza vaccine formulations used in this study and its TLR7
dependency in vitro. In pDCs of wild-type mice cultured from bone
marrow cells (Figure 4A, black bars) or enriched from splenocytes
(Figure 4B, black bars) WIV but not SV or SU induced IFNa
production. In bone marrow-derived pDCs from TLR7
2/2 mice,
IFNa production upon incubation with WIV was strongly
decreased as compared to wild-type DCs (Figure 4A), confirming
the results of others [22]. However, spleen-derived pDCs from
TLR7
2/2 mice exposed to WIV produced similar amounts of
IFNa as compared to pDCs from wt mice (Figure 4B). Thus, while
in pDCs cultured from bone marrow induction of IFNa
production by WIV is strictly dependent on TLR7, in pDCs
enriched directly from spleen cells it is independent of TLR7. This
implies that bone marrow pDCs and spleen pDCs are not
completely identical. In line with this notion, bone marrow pDCs
and spleen pDCs were earlier found to respond differently to HSV
virus infection with respect to the TLR9 dependency of the IFNa
response [28]. Our results show that WIV is indeed able to induce
IFNa in a TLR7-independent way. This may also be the case in
the in vivo situation, where in accordance with its well-described
adjuvant functions IFNa may lead to the production of Th1 type
antibodies in TLR-deficient mice [26].
Possible TLR-independent pathways activated by WIV may
involve the retinoic acid-inducible gene (RIG-I) [29–32]. RIG-I is a
cytoplasmic RNA-helicase that recognizes influenza virus by
binding viral ssRNA bearing 59-triphosphates which leads to
IFNa production [33,34]. The inactivated virus particles in WIV
vaccine retained their membrane-fusion property (Text S2) and
part of the viral genomes could therefore have entered the target
cell cytoplasm to be sensed by RIG-I.
Taken together our observations show that the superior
immune response to WIV, relative to that to SV or SU vaccines,
is driven primarily by TLR-dependent mechanisms. Herein the
presence of the viral RNA in the vaccine seems to play a crucial
role. In contrast to SV and SU vaccines WIV contains substantial
amounts of viral RNA. Removal of ssRNA from WIV by
detergent solubilization and ultracentrifugation followed by
reconstitution of the viral membrane envelopes to virosomes
abolishes the capacity of the vaccine to induce production of IFNa
by pDCs in vitro (Text S3 and Figure S1A) and type 1 immune
responses in vivo [15]. On the other hand, ssRNA purified from
WIV and condensed with polyethylenimine (PEI) did induce IFNa
production in vitro (Text S3 and Figure S1B). Obviously, exposure
of the viral RNA to b-propiolactone in the course of virus
inactivation leaves the RNA intact to trigger TLR7-mediated
signaling pathways (Figure 4), which translates into a strong and
Th1-skewed antibody response to WIV in wild-type mice. In
addition, the viral RNA may contribute to the TLR-independent
part of the response to WIV since TLR7-independent production
of IFNa could only be induced in pDCs by WIV and not by
formulations (SV, SU, or reconstituted viral envelopes) which lack
viral RNA (Figure 4B) [15]. These lines of evidence point to the
ssRNA in WIV as the key component that enhances and steers the
adaptive immune response by involvement of innate immune
mechanisms.
IFNa induction in pDCs clearly discriminates WIV from SV
and SU vaccines but seems to occur independent of TLR7. The
fact that the immune response to WIV is predominantly
dependent on TLR7 then suggests that other TLR7-mediated
mechanisms, possibly involving conventional DCs and B cells,
critically contribute to the immune reaction. Recently, an in vitro
study on B cells showed that TLR7 stimulation or CD40-CD40L
binding by itself triggers IgG1 antibody production, but when
simultaneously present induce proliferation and a switch to IgG2a
production [25]. Additional stimulation of IFNa/b receptors on
the same cells further drives the production of IgG2a at the
expense of IgG1 antibodies [25]. Although this model might
represent an over-simplification of the in vivo situation, it is in line
with our data. The different scenarios encountered upon
immunization of wild-type and mutant mice with WIV, SV, or
SU are summarized in Table 2. WIV provides the ssRNA for
direct triggering of TLR7 in B cells as well as the CD40 ligand for
CD40 stimulation on B cells through strong T helper cell
induction, which was shown also to depend on TLR7 signalling.
Together with IFNa produced by TLR7-mediated and/or TLR7-
independent mechanisms, these signals will lead to the enhanced
and strongly polarized Th1-type antibody responses characteristic
for WIV. In the absence of TLR7, WIV-induced IFNa can still
stimulate moderate production of Th1 type antibodies and
increase the total IgG. In contrast, SV and SU vaccines are poor
inducers of T helper cells and IFNa, and cannot stimulate B cells
directly via TLR7. Consequently, SV and SU vaccines induce
lower and more Th2-polarized antibody responses.
Our data provide mechanisms which explain the superiority of
WIV vaccine to prime HA-specific immune responses in mice.
Whether similar mechanisms are operational in humans and
contribute to the stronger immunogenicity of WIV compared to
Figure 4. Induction of IFNa by WIV is TLR7-dependent in bone-marrow derived pDCs, but not in spleen-derived pDCs. Bone-marrow
cells cultured with FLT3L (containing 20–30% pDCs) (A), or pDC-enriched spleen cell cultures (containing 62%–68% pDCs) (B) of wild-type mice (black
bars) and TLR7
2/2 mice (white bars) were incubated overnight with WIV, SV, or SU vaccine. IFNa was measured in cell supernatants by sandwich
ELISA. Bars represent average values of triplicate determinations with standard deviation, and are representative of three independent experiments.
doi:10.1371/journal.ppat.1000138.g004
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Despite the favourable immunogenic properties of WIV, recent
clinical trials performed in the context of pandemic vaccine
development show that even with WIV at least two immunizations
with a substantial amount of antigen (15–30 mg) and/or the
addition of adjuvants will probably be required to achieve immune
responses that comply with the CPMP criteria. If TLRs are
involved in the priming of humans with WIV, their role during
recall responses may be less critical, given the fact that in general
WIV, SU, and SV induce similar HI titres in primed populations
[11]. Use of WIV derived from wild-type virus instead of
recombinant vaccine strains resulted in good antibody titres even
without the addition of adjuvants and might thus be an option to
obtain satisfying immune responses [35]. Evaluation of adjuvants
in combination with WIV in clinical trials is so far restricted to
aluminium salts. However, where adjuvanted and non-adjuvanted
WIV were compared side-by-side, effects of this Th2 adjuvant on
vaccine efficacy were absent, poor, or inconsistent [36]. So, better
adjuvants have to be found that work synergistically with WIV in
order to exploit the full potential of intact inactivated virus
particles as vaccines.
In conclusion, our data reveal, for the first time to our
knowledge, that TLRs play an eminent role in the immune
responses to a classic influenza vaccine. Of the three influenza
vaccine formulations studied here, only WIV efficiently triggered
TLR7-mediated mechanisms leading to superior immune re-
sponses. Processing of inactivated whole virus particles into SV or
SU eliminates the immuno-potentiating effect of the viral ssRNA,
the primary PAMP in WIV vaccine, and results in a loss of
quantity and shift in the quality of the immune response. Thus,
TLR-dependent mechanisms appear to form the basis for WIV’s
antigen-sparing quality and hence its recognized strong potential
as a pandemic vaccine candidate [7,12]. Optimizing TLR7-
signalling by rational vaccine design may produce even more
potent vaccines, which are urgently needed in the face of the
current influenza pandemic threat.
Methods
Vaccines and reagents
H5N1 virus (NIBRG-14, a 2:6 recombinant of A/Vietnam/
1194/2004 [H5N1] and A/PR/8/34 [H1N1] virus produced by
reverse genetics technology) was provided by the National Institute
for Biological Standards and Controls (NIBSC; Potters Bar, UK),
propagated on embryonated chicken eggs, inactivated with 0.1%
b-propiolactone to obtain WIV, and processed into split virus
vaccine or subunit vaccine according to standard procedures
[37,38]. The haemagglutinin protein concentration in the vaccines
was determined by single radial immunodiffusion (SRID) [39].
Endotoxin levels in all vaccines met the requirements of the
European Pharmacopoeia standard. (If, nevertheless, contamina-
tion of endotoxin [signalling via TLR4] would have played an
important role we should have observed substantial differences in
the response between TLR7-deficient mice [capable of signalling
via TLR4)]and MyD88/TRIF-deficient mice [deficient in all
TLR-derived signalling]. However, such differences were not
found for any of the vaccines.) CpG DNA (ODN D19) was
purchased from Eurogentec (Seraing, Belgium).
Mice and vaccination
For immunization experiments, C57BL/6, TLR7
2/2 and
MyD88
2/2/TRIF
2/2 mice (generated from MyD88
2/2 mice
[40] and TRIF
2/2 mice [41]) were bred at the University of
Massachusetts Medical School (Worcester, MA). For in vitro
studies, 10- to 12-week-old female C57BL/6 mice were purchased
from Harlan Netherlands B.V. (Zeist, The Netherlands), and
TLR7
2/2 mice (a gift from S. Akira and C. Reis e Sousa) were
bred at the University Medical Center Groningen. All experiments
were conducted with approval of the local Institutional Animal
Care and Use Committees. Mouse groups were matched for sex
and age. Groups (n=6–8) of C57BL/6, TLR7
2/2, and MyD88
2/
2/TRIF
2/2 mice were intramuscularly injected with 50 ml of PBS
in each calf muscle containing a total of 5 mg haemagglutinin
protein per mouse of either WIV, SV, or SU vaccine formulation
or no vaccine as a control. At 28 days after immunization, sera and
spleens were collected for evaluation.
Quantitative PCR
Relative viral RNA content of the different vaccines was
determined using a two-step real-time RT-PCR assay amplifying a
193-bp fragment within the M1 gene of influenza A viruses. For
this purpose RNA was extracted from WIV, SV, or SU (5 mg HA)
with the QIAamp viral RNA Mini Kit (QIAGEN, Venlo, The
Netherlands), cDNA synthesis was performed on 5 ml of viral
RNA (one-tenth of the final elution volume) using the Verso
cDNA kit from ABgene (Westburg, Leusden, The Netherlands),
and 1 mM UNI12 primer (59-AGCAAAAGCAGG-39, corre-
sponding to viral noncoding nucleotides 1 to 12 [42]). Real-time
PCR was performed with 200 nM M1-FOR primer (59-
CCTGGTATGTGCAACCTGTG-39) and M1-REV primer (59-
AGCCTGACTAGCAACCTCCA-39); purchased from Eurogen-
tec, and the Absolute QPCR SYBR Green Mix (ABgene).
Amplification was performed on a StepOne apparatus (Applied
Biosystems), and consisted of 15 min initial activation at 95uC,
Table 2. Putative vaccine effects contributing to different adaptive immune responses based on the model proposed by Heer et
al. [25].
Vaccine Mouse Strain Direct Vaccine Effects Result
IFNa Production Th Cell Induction
TLR7-Mediated B-Cell
Stimulation
Antibody
Response Phenotype
WIV wt + ++ + +++ Th1
TLR7
2/2 ++ 2 ++ Th1/Th2
SV/SU wt 2 + 2 + Th2
TLR7
2/2 2 + 2 + Th2
Differences in responses induced in either wild-type or TLR7-deficient mice by WIV and SV or SU vaccine are given semiquantitatively for each of the indicated facets of
the innate or adaptive response.
doi:10.1371/journal.ppat.1000138.t002
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60uC. In each experiment, a standard curve (R
2.0.99 within the
range of 1610
2 to 1610
9 copies per reaction) was drawn to
convert the respective cycle threshold (Ct) values into the number
of viral genome copies. This standard consisted of a pCR2.1-
TOPO plasmid construct in which was cloned a 473-bp sequence
of influenza A/Puerto Rico/8/34 segment 7.
Haemagglutination inhibition assay
The HI assay was performed as described before [15]. Briefly,
heat-inactivated mouse serum was absorbed to 3 volumes 25%
kaolin/PBS (Sigma-Aldrich, Inc., St. Louis, MO), 20 min at room
temperature (RT). After centrifugation, 50 ml of supernatant was
serially diluted two-fold in a round-bottom microtitre plate
(Costar, Corning Inc., Corning, NY), in duplicate. Subsequently,
50 ml PBS was added containing 2 HAU of H5N1 (NIBRG-14)
virus and incubated for 40 min at RT. We used 2 HAU of virus
instead of the standard 4 HAU to increase the sensitivity of the
assay. Finally, 50 ml of 1% guinea pig erythrocytes (Harlan) in PBS
was added to each well and HI titres were determined after 2 h
incubation at room temperature. HI titres are given as the
reciprocal of the highest serum dilution producing complete
inhibition of haemagglutination.
Virus-neutralization assay
The levels of virus-neutralizing (VN) serum antibodies were
determined with a VN assay [15,43]. The VN titre was defined as
the reciprocal of the highest serum dilution capable of inhibiting
200 TCID50 of H5N1 vaccine strain virus (NIBRG-14) from
infecting Madin-Darby canine kidney cell monolayers in a
microtiter plate. Infection was measured by an ELISA on
intracellularly produced viral NP protein. Inhibition of infection
by simultaneous incubation with mouse serum was established if
the ELISA absorbance value (A492) measured was below the cut-
off value, determined by the equation: [(average A492 of the
positive controls (infected cells) minus average A492 of the negative
controls (non infected cells)) divided by 2] plus the average A492 of
the negative controls. Serum samples were tested in quadruplicate.
Isotype ELISA
Microtitre plates (Greiner, Alphen a/d Rijn, The Netherlands)
were coated with 0.2 mg influenza H5N1 (NIBRG-14) subunit
vaccine per well in 100 ml coating buffer, overnight. After blocking
with 2% milk in coating buffer for 45 min, 100 ml of two-fold serial
dilutions of serum samples in 0.05%Tween 20/PBS (PBS/T) were
applied to the wells and incubated for 1.5 h, in duplicate.
Subsequently, 100 ml of horseradish peroxidase-conjugated goat
anti-mouse IgG-isotype antibody (Southern Biotech, Birmingham,
Alabama) was applied for 1 h. All incubations were performed at
37uC. Staining was performed using o-phenylene-diamine (OPD)
(Eastman Kodak Company) and absorbance was read at 492 nm
(A492) with an ELISA reader (Bio-tek Instruments, Inc.). After
subtraction of background levels, serum dilutions yielding an OD
of 0.2 were calculated using linear regression, of which the
reciprocal of the average of the duplicates represents the titre.
IFNc and IL4 Elispot assays
This assay was performed as described previously [15]. In short,
erythrocyte-depleted splenocytes were seeded at a concentration of
5610
5 cells in 100 ml medium per well, in triplicate in a microtitre
plate (Greiner), which was pre-coated with anti-IFNc or anti-IL4
capture antibody (Pharmingen, San Diego, CA) and blocked with
4% BSA/PBS (Sigma-Aldrich). Cells were stimulated with 1 mg
H5N1 (NIBRG-14) subunit vaccine per well, overnight in a
humidified CO2 incubator at 37uC. Cells were lysed with 100 mlo f
H2O per well and plates were washed extensively, after which
100 ml of biotinylated anti-IFNc or anti-IL4 (Pharmingen) in 2%
BSA/PBS was added 1 h at 37uC. Subsequently, the plates were
incubated with 100 ml of alkaline phosphatase conjugated
streptavidin (Pharmingen) in 2% BSA/PBS for 1 h at 37uC, spots
were visualized with 5-bromo-4-chloro-3-indolylphosphate (Sig-
ma-Aldrich) substrate immobilized in solidified agarose. Plates
were scanned and spots were counted manually.
Plasmacytoid dendritic cells
Plasmacytoid DCs were generated from bone marrow cells of
C57BL/6 or TLR7
2/2 mice by seeding 1–2610
6 bone marrow
cells per well of a 24-well plate and culturing the cells for one week
in Iscove’s Modified Dulbecoo’s Medium (IMDM) with 10% FCS
and 100 ng/ml FLT3L (R&D Systems, Abingdon, UK) [22].
Single splenocyte suspensions were produced by collagenase D
(Roche Diagnostics GmbH, Germany) treatment of the spleens,
and spleen cell populations enriched for plasmacytoid DCs (pDCs)
were obtained after magnetically labelling of pDCs with anti-
mPDCA-1 antibody conjugated MicroBeads (Miltenyi Biotech
GmbH, Germany) and separation over a MACS Column
(Miltenyi), according to the manufacturers protocol. Percentages
of pDCs in the positively selected population were determined by
FACS analysis using anti-mPDCA-1-PE antibody (Miltenyi) and
anti-CD11c-FITC (GeneTec Inc., Canada). Cell suspensions
containing 1–2610
5 pDCs in 100 ml were seeded in a microtitre
plate and stimulated in triplicate with an equal volume containing
1.0 mg HA of either WIV, SV, or SU vaccine, or 1.0 nmol CpG
DNA. After 20 h of incubation in a humidified CO2 incubator at
37uC, supernatants were collected and subjected to the IFNa
ELISA.
IFNa ELISA
IFNa detection in cell-culture supernatants was performed using
a sandwich ELISA as described previously [15]. IFNa concentra-
tions were calculated from a recombinant IFNa (HyCult,
Biotechnology, Uden, The Netherlands) standard curve performed
in quadruplicate using linear regression, and expressed in units per
ml.
Statistics
Statistical analysis on HI titres, antibody titres, and Elispot
counts was performed with SPSS (SPSS 1202 Inc., Chicago, IL)
using the Mann-Whitney U test with a CI of 95%. All p values are
two-tailed. Statistical significance was defined as p,0.05.
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